$Grifols (GRFS.US)$ April 22, 2024 Grifols achieves positive...
$Grifols(GRFS.US$ April 22, 2024 Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease Download PDF Grifols’ Fanhdi showed it could be effective, safe and well tolerated in the management of bleeding episodes and for the prevention of bleeding during surgeries in patients with von Willebrand Disease (VWD) VWD, which is caused by a deficiency of von Willebrand factor in plasma, is the most common hereditary blood-clotting disorder1 Grifols remains commited to providing innovative plasma therapies that treat a variety of life-threatening diseases and conditions that impact patients worldwide Barcelona, Spain, April 22, 2024 – Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and a pioneer in rare disease treatment, today announced that its recently concluded observational phase 4 study of Fanhdi®, Grifols’ double-inactivated human anti-hemophilic factor, showed positive results in the product’s safety and efficacy as prophylaxis and treatment in patients with von Willebrand Disease (VWD). Grifols will present the data today at the World Hemophilia Federation 2024 World Congress, in Madrid. VWD is an incurable bleeding disorder that affects the ability of blood to clot properly. It's the most common hereditary blood-clotting disorder and in Spain alone, this rare disease is estimated to impact 122 patients per million2. Grifols conducted this phase 4, observational, multi-center, prospective cohort study to evaluate the safety and clinical efficacy of long-term use of Fanhdi in subjects with VWD. The overall clinical efficacy of treatment with Fanhdi (including on-demand and prophylaxis) achieved 100% excellent and/or good (n=15 patients) rated by the investigator, with no safety concerns raised throughout the study. “This observational study further reinforces the potential long-term effectiveness of Fanhdi in the treatment of bleeding episodes and as prophylaxis before surgical procedures,” said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. “Grifols continues to develop and provide advanced lifesaving therapies for patients in need.” A total of 17 participants were enrolled in the 12-month study, 15 of them receiving at least one dose of Fanhdi®. The efficacy was assessed during 46 bleeding episodes reported for nine (60%) subjects, and six surgical/invasive procedures reported for six (33.3%) subjects.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
